Home » Saihari Sadanandan Case Series

Dr. Saihari Sadanandan Case Series on Aggrastat 

Dr. Saihari Sadanandan presents a case series on the contemporary use of glycoprotein IIb/IIIa inhibitors (GPIs). 

The series is based on cases where patient treatment included Aggrastat (tirofiban hydrochloride) injection and is intended to be an educational resource for fellows and those who may not be familiar with the use of GPIs. 

These cases and testimonials are based on the experiences of a few people. Not all cases are identical. You are not likely to have similar results. 

Important Safety Information about the use of Aggrastat is provided below. 

Clinical studies performance with Aggrastat are provided in the full Prescribing Information. c

About Dr. Saihari Sadanandan

Dr. Saihari Sadanandan is the Director of Tampa Cardiovascular Interventions and Research and an interventional cardiologist at three different hospitals in Tampa; St. Joseph’s Main Hospital, St. Joseph’s Hospital North, and Advent Health Carrollwood Hospital. Here he presents three cases where he used Aggrastat in his practice:

  • ACS with no DAPT pre-procedure
  • Intraprocedural thrombus formation
  • Short infusion administration in a NSTE-ACS patient
Dr. Saihari Sadanandan was provided financial support from Medicure Inc. for these videos.

ACS with no DAPT Pre-Procedure

A patient presents to the Emergency Department with Acute Coronary Syndrome (ACS) and has not received dual-antiplatelet therapy (DAPT) prior to a PCI procedure.

Intraprocedural Thrombus Formation

A case where intravenous Aggrastat is used in a patient who had an intraprocedural thrombus in their coronary arteries. 

Short Infusion Administration in Patient with NSTE-ACS

A patient presents to the Emergency Department with NSTE-ACE and is treated with short infusion Aggrastat. 

About Aggrastat

Aggrastat (tirofiban hydrochloride) is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Aggrastat:

  • Offers protection during the delayed onset of the oral P2Y12 agents*
  • Has a rapid onset, achieving >90% platelet aggregation inhibition within 10 minutes1
  • Is reversible: platelets return to baseline function within 4 to 8 hours of discontinuation of infusion
  • Has no contraindication for patients on hemodialysis
  • Has no drug interactions with oral P2Y12 inhibitors*

* Concomitant use of fibrinolytic, anticoagulants and antiplatelet drugs increases the risk of bleeding.

1 Mardikar HM et al. Am Heart J. 2007;154(344):e1-5
Aggrastat Pharmacy Product

See Cases from Other Interventional Cardiologists 

Check out the experience of other healthcare providers in the US that use Aggrastat to reduce the rate of thrombotic complications for their patients during PCI.

Dr. Barry Bertolet

Dr. Kevin Ariani

Dr. Deepak Talreja

Click to see the full list of available cases. 

Important Safety Information

Indication:

Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Contraindications:

  • Known hypersensitivity to any component of Aggrastat®.
  • History of thrombocytopenia with prior exposure to Aggrastat®.
  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.

Warnings and Precautions:

  • Aggrastat® can cause serious bleeding. Most bleeding associated with Aggrastat® occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue Aggrastat®.
  • Thrombocytopenia: discontinue Aggrastat® and heparin.

Adverse Reactions:

  • Bleeding is the most commonly reported adverse reaction.

For additional information, refer to the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.
x

Subscribe